X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SANOFI INDIA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SANOFI INDIA FULFORD INDIA/
SANOFI INDIA
 
P/E (TTM) x 398.8 38.4 1,038.2% View Chart
P/BV x 6.2 7.2 85.8% View Chart
Dividend Yield % 0.1 0.5 16.1%  

Financials

 FULFORD INDIA   SANOFI INDIA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SANOFI INDIA
Dec-17
FULFORD INDIA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs9424,945 19.0%   
Low Rs4503,901 11.5%   
Sales per share (Unadj.) Rs691.41,081.8 63.9%  
Earnings per share (Unadj.) Rs11.5141.6 8.1%  
Cash flow per share (Unadj.) Rs15.4185.9 8.3%  
Dividends per share (Unadj.) Rs2.0033.00 6.1%  
Dividend yield (eoy) %0.30.7 38.5%  
Book value per share (Unadj.) Rs380.0868.8 43.7%  
Shares outstanding (eoy) m3.9023.03 16.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.1 24.6%   
Avg P/E ratio x60.731.2 194.3%  
P/CF ratio (eoy) x45.323.8 190.5%  
Price / Book Value ratio x1.85.1 36.0%  
Dividend payout %17.423.3 74.9%   
Avg Mkt Cap Rs m2,714101,862 2.7%   
No. of employees `0000.43.2 13.7%   
Total wages/salary Rs m5053,685 13.7%   
Avg. sales/employee Rs Th6,073.07,691.9 79.0%   
Avg. wages/employee Rs Th1,137.41,137.7 100.0%   
Avg. net profit/employee Rs Th100.71,006.5 10.0%   
INCOME DATA
Net Sales Rs m2,69624,914 10.8%  
Other income Rs m125807 15.5%   
Total revenues Rs m2,82225,721 11.0%   
Gross profit Rs m-465,372 -0.9%  
Depreciation Rs m151,022 1.5%   
Interest Rs m1011 86.4%   
Profit before tax Rs m545,146 1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m101,886 0.5%   
Profit after tax Rs m453,260 1.4%  
Gross profit margin %-1.721.6 -8.0%  
Effective tax rate %17.736.6 48.2%   
Net profit margin %1.713.1 12.7%  
BALANCE SHEET DATA
Current assets Rs m1,73814,432 12.0%   
Current liabilities Rs m5456,010 9.1%   
Net working cap to sales %44.333.8 130.9%  
Current ratio x3.22.4 132.9%  
Inventory Days Days4861 79.6%  
Debtors Days Days428 15.1%  
Net fixed assets Rs m127,991 0.1%   
Share capital Rs m39230 16.9%   
"Free" reserves Rs m1,44319,778 7.3%   
Net worth Rs m1,48220,008 7.4%   
Long term debt Rs m00-   
Total assets Rs m2,07727,770 7.5%  
Interest coverage x6.7468.8 1.4%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.9 144.7%   
Return on assets %2.611.8 22.2%  
Return on equity %3.016.3 18.5%  
Return on capital %4.325.8 16.7%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m176,306 0.3%   
Fx outflow Rs m6735,257 12.8%   
Net fx Rs m-6561,049 -62.5%   
CASH FLOW
From Operations Rs m904,351 2.1%  
From Investments Rs m105-787 -13.3%  
From Financial Activity Rs m-14-1,884 0.7%  
Net Cashflow Rs m1811,680 10.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 3.8 14.4 26.4%  
FIIs % 0.1 14.6 0.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.5 201.9%  
Shareholders   4,783 15,184 31.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS